The preliminary result of proton and carbon ion therapy for recurrent chordoma and chondrosarcoma of skull base and cervical spine
10.3760/cma.j.issn.0254-5098.2020.06.004
- VernacularTitle:质子碳离子治疗复发性颅底及颈椎脊索瘤和软骨肉瘤的初步临床结果
- Author:
Xiyin GUAN
1
;
Jing GAO
;
Jiyi HU
;
Weixu HU
;
Jing YANG
;
Chaosu HU
;
Lin KONG
;
Jiade LU
Author Information
1. 上海市质子重离子医院放射治疗科 上海质子重离子放射治疗工程技术研究中心 201321
- From:
Chinese Journal of Radiological Medicine and Protection
2020;40(6):434-438
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the short-term tumor control and toxicity of recurrent skull base and cervical spine chordoma and chondrosarcoma in patients treated with pencil beam scanning proton and heavy ion therapy.Methods:Between June 30 th, 2014 and July 30 th, 2018, a total of 45 skull base and cervical spine chordoma ( n=39) and chondrosarcoma ( n=6) patients (28 males and 17 females; mean age at initial presentation of 44 years, range, 14-76 years) were treated in our center for the course of radiotherapy. The median maximum tumor volume was 57 cm 3 (range, 6.6-231.7 cm 3). There were 31 post-operative recurrent patients and 14 post-operative and post-radiated recurrent patients. One patient received proton therapy, 21 patients received combined proton and carbon ion therapy, 23 patients received carbon ion therapy. Results:All patients completed the whole course of the treatment. The median follow-up time was 29 months (range: 8-57 months), the 2-year overall survival (OS), local control (LC), and progression-free survival (PFS) were 82.7%, 85.3%, and 73.8%, respectively. There were no other grade 3-4 acute or late radiation-induced toxicity except one grade 3 acute mucositis. The 2-year OS rates for patients after first-time radiation vs. re-irradiation were 96.2% and 50.3% ( χ2=16.969, P<0.05). Conclusions:The short-term outcomes of pencil beam scanning proton and heavy ion therapy for recurrent skull base and cervical spine chordoma and chondrosarcoma is favorable. Further study is needed for long-term efficacy and safety.
